Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)
British Journal of Dermatology · 07.07.2023 · 189 (1) · 23-32
DOI: 10.1093/bjd/ljad096 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 31.03.2023. Verfasst von Antonio Torrelo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents, Janus Kinase Inhibitors. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Background
Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.
Objectives
To evaluate the efficacy and safety of three doses of baricitinib in combination with low-to-moderate potency topical corticosteroids in paediatric patients with moderate-to-severe AD.
Methods
Patients (aged 2 to < 18 years) were randomized (1 : 1 : 1 : 1) to once-daily baricitinib low dose (1 mg equivalent), medium dose (2 mg equivalent), high dose (4 mg equivalent) or placebo for 16 weeks. The primary endpoint was the proportion of patients achieving a validated Investigator Global Assessment® (vIGA-AD) of 0/1 with a ≥ 2-point improvement at week 16. Key secondary endpoints included the proportions of patients achieving ≥ 75% and ≥ 90% improvement in the Eczema Area and Severity Index (EASI-75 and EASI-90, respectively), ≥ 75% improvement in the SCORing Atopic Dermatitis (SCORAD 75), mean change from baseline in EASI score and proportion of patients achieving a 4-point improvement in the Itch Numeric Rating scale (NRS) for patients aged ≥ 10 years. Primary and key secondary efficacy analyses were conducted on the intent-to-treat population and adjusted for multiplicity. Safety analyses included all randomized patients who received ≥ 1 dose of study treatment.
Results
A total of 483 patients were randomized (mean age 12 years). The baricitinib 4 mg equivalent achieved a statistically significant (P < 0.05) improvement vs. placebo on all 16-week endpoints (vIGA 0/1 with ≥ 2-point improvement, EASI-75, EASI-90, SCORAD 75, mean change in EASI score and Itch NRS 4-point improvement for patients aged ≥ 10 years). Improvement (P < 0.05, non-multiplicity adjusted) was also observed for baricitinib 4 mg equivalent vs. placebo in the ability to fall asleep and in reduction of topical corticosteroid use. Few patients discontinued due to adverse events (1.6% for placebo and 0.6% for those treated with baricitinib). There were no deaths, venous thromboembolic events, arterial thrombotic events, major adverse cardiovascular events, malignancies, gastrointestinal perforations or opportunistic infections seen.
Conclusions
The results indicate that baricitinib offers a potential therapeutic option with a favourable benefit–risk profile for paediatric patients with moderate-to-severe AD who are candidates for systemic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
- Diamond Clinic, Kraków, Poland.
- Dermatology Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
- Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Dermatology, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
- Department of Dermatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Förderung
- Eli Lilly and Company
Zitieren
APA
Torrelo, A., Rewerska, B., Galimberti, M., Paller, A., Yang, C. Y., Prakash, A., Zhu, D., Pontes Filho, M. A. G., Wu, W. S., & Eichenfield, L. F. (2023). Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). British Journal of Dermatology, 189(1), 23-32. https://doi.org/10.1093/bjd/ljad096
Vancouver
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). British Journal of Dermatology. 2023;189(1):23-32. doi:10.1093/bjd/ljad096
BibTeX
@article{Torrelo2023,
author = {Torrelo, Antonio and Rewerska, Barbara and Galimberti, Maria and Paller, Amy and Yang, Chin-Yi and Prakash, Apurva and Zhu, Danting and Pontes Filho, Marco Antonio G and Wu, Wen-Shuo and Eichenfield, Lawrence F},
title = {Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)},
journal = {British Journal of Dermatology},
year = {2023},
volume = {189},
number = {1},
pages = {23--32},
doi = {10.1093/bjd/ljad096}
}
EUVIMED